Format

Send to

Choose Destination
Am J Rhinol Allergy. 2019 Mar;33(2):203-211. doi: 10.1177/1945892418814768. Epub 2018 Dec 27.

Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.

Author information

1
1 Department of Otolaryngology, Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois.
2
2 Department of Internal Medicine. Affiliate clinician: Loyola University Medical Center, Maywood, Illinois.

Abstract

BACKGROUND:

Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population.

OBJECTIVE:

The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitis patients by reviewing literature and clinical trials.

METHODS:

A comprehensive review of literature and clinical trials-both recently completed and ongoing-was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitis patients-including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme.

RESULTS:

Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed.

CONCLUSION:

These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease.

KEYWORDS:

GATA-3 DNAzyme; Hgd40; SB010; anti-IL-13; anti-IL-4; anti-IL-5; anti-IgE; benralizumab; biologic agents; chronic rhinosinusitis; dupilumab; mepolizumab; nasal polyposis; omalizumab; reslizumab

PMID:
30587005
DOI:
10.1177/1945892418814768

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center